Pephexia Therapeutics ApSAktiv
Økonomiske nøgletal
Nøgletal
2025Balancens sammensætning
Selskabsskat
Virksomheden er sambeskattet. Skatten opgøres samlet hos administrationsselskabet Fogtmann Fosgerau Holding ApS.
Kilde: Skattestyrelsens offentlige skattelister for selskaber. Beregnet skat for indkomståret; kan være lavere end 22 % af indkomsten, fx ved skat betalt i udlandet. sktst.dk
Regnskabstal2020–2025
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Balance — aktiver | ||||||
| Likvide beholdninger | 707.036 | 3.528.850 | 6.647.008 | 2.613.067 | 3.843.726 | 292.479 |
| Omsætningsaktiver i alt | 788.358 | 4.812.136 | 9.746.400 | 5.214.782 | 5.856.816 | 1.979.537 |
| Anlægsaktiver i alt | 143.556 | — | — | 36.690 | 36.690 | 36.690 |
| Aktiver i alt | 931.914 | 4.812.136 | 9.746.400 | 5.251.472 | 5.893.506 | 2.016.227 |
| Balance — passiver | ||||||
| Kortfristede gældsforpligtelser | 105.557 | 374.671 | 4.431.108 | 1.165.128 | 1.014.266 | 308.661 |
| Langfristede gældsforpligtelser | — | 7.089.534 | 12.461.503 | 16.672.286 | 20.186.052 | 21.454.911 |
| Gældsforpligtelser i alt | 105.557 | 7.464.205 | 16.892.611 | 17.837.414 | 21.200.318 | 21.763.572 |
| Selskabskapital | 52.286 | 58.570 | 62.387 | 62.387 | 66.547 | 66.547 |
| Overført resultat | 630.515 | -2.710.639 | -7.208.598 | -12.648.329 | -15.373.359 | -19.813.892 |
| Årets resultat | -129.817 | -4.532.328 | -6.677.466 | -5.439.731 | -5.320.870 | -4.440.533 |
| Egenkapital i alt | 794.775 | -2.652.069 | -7.146.211 | -12.585.942 | -15.306.812 | -19.747.345 |
| Resultatopgørelse | ||||||
| Omsætning | — | 626.000 | — | — | — | — |
| Bruttofortjeneste | — | — | -5.266.259 | -3.212.128 | -2.085.438 | -179.735 |
| Resultat af primær drift | -146.499 | -5.598.838 | -7.864.015 | -6.013.345 | -5.800.907 | -4.376.284 |
| Resultat før skat | -151.906 | -5.713.083 | -8.548.065 | -6.971.675 | -6.821.313 | -5.691.336 |
| Årets resultat | -129.817 | -4.532.328 | -6.677.466 | -5.439.731 | -5.320.870 | -4.440.533 |
| Personaleomkostninger | 0 | 860.801 | 2.597.756 | 2.801.217 | 3.715.469 | 4.196.549 |
| Af- og nedskrivninger | — | — | — | — | — | — |
| Andre nøgletal | ||||||
| Ansatte | 0 | 1 | 3 | 3 | 4 | 4 |
En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.
Om virksomheden
Årsrapport 2025Description of key activities of the companyLike previous years, the activities are to develop new medicines for the treatment of diseases and thereby achieve future revenues from research and development.
Significant changes in the company's activities and financial mattersThere have been no significant changes in activities and financial matters. The gross loss for the year totals DKK -179.735 against DKK -2.085.438 last year. Profit or loss from ordinary activities after tax totals DKK -4.440.533 against DKK -5.320.870 last year. Management considers the net profit or loss for the year satisfactory. Capital lossThe company has lost the equity and is thereby included in regulation of the Danish Company Act. art. 119. It is the management's expectation, that the share capital will be reestablished by a combination of capital increase and future earnings.
Uddrag af ledelsesberetningen i den seneste årsrapport.